Expected Value of Sample Information Calculations in Medical Decision Modeling

Medical Decision Making

Volumn 24, Issue 2, 2004, Pages 207-227

  Ades, A E ^a   Lu, G ^a   Claxton, K ^b  

^a MRC Health Services Research Collaboration   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Epidemiology; Expected value of sample information; Odds ratios; Random effects

Indexed keywords

ARTICLE; CALCULATION; DECISION MAKING; EPIDEMIOLOGICAL DATA; EVALUATION; EVIDENCE BASED MEDICINE; HUMAN; INFORMATION PROCESSING; MEDICAL RESEARCH; MONTE CARLO METHOD; PROBABILITY; RANDOMIZATION; RISK; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

ALGORITHMS; DECISION SUPPORT SYSTEMS, CLINICAL; GREAT BRITAIN; INFORMATION MANAGEMENT; MODELS, STATISTICAL; MONTE CARLO METHOD; ODDS RATIO;

EID: 1642369384     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X04263162     Document Type: Article

References (68)

1. Stinnett A, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analyses. Med Decis Making. 1998;18:S68-S80.
2. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of heath care technologies. J Health Econ. 1999;18:341-64.
3. Schlaiffer R. Probability and Statistics for Business Decisions. New York: McGraw-Hill; 1958.
4. Raiffa H, Schlaiffer R. Applied Statistical Decision Theory. New York: Wiley Interscience; 1967.
5. Finkel AS, Evans JS. Evaluating the benefits of uncertainty reduction in environmental health risk management. J Air Pollut Control Assoc. 1987;37:1164-71.
6. Reichard EG, Evans JS. Assessing the value of hydrogeologic information for risk-based remedial action decisions. Water Resour Res. 1989;25:1451-60.
7. Taylor AC, Evans JS, McKone TE. The value of animal test information in environmental control decisions. Risk Anal. 1993;13:403-12.
8. Thompson KM, Evans JS. The value of improved national exposure information for perchloroethylene (Perc): a case study for dry cleaners. Risk Anal. 1997;17:253-71.
9. Felli JC, Hazen GB. Sensitivity analysis and the expected value of perfect information. Med Decis Making. 1998;18:95-109.
10. Fenwick E, Claxton K, Sculpher M, Briggs A. Improving the Efficiency and Relevance of Heath Technology Assessment: The Role of Iterative Decision Analytic Modelling. Report no. 179. York, United Kingdom: Centre for Health Economics, University of York; 2000.
11. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ. 1996;5:513-24.
12. Davis DR, Kisiel CC, Duckstein L. Bayesian decision theory applied to design in hydrology. Water Resour J. 1972;8:33-41.
13. Wagner BJ. Sampling design methods for groundwater modelling under uncertainty. Water Resour J. 1995;31:2581-91.
14. Dakins ME, Toll JE, Small MJ, Brand KP. Risk-based environmental remediation: Bayesian Monte Carlo analysis and the expected value of sample information. Risk Anal. 1996;16:67-79.
15. Claxton K, Lacey LF, Walker SG. Selecting treatments: a decision theoretic approach. Journal of the Royal Statistical Society (A). 2000;163:211-26.
16. Phillips CV. The economics of more research is needed. Int J Epidemiol. 2001;30:771-6.
17. Sterne JAC, Davey SG. Sifting the evidence - what's wrong with significance tests. BMJ. 2001;322:226-31.
18. Peto R, Baigent C. Trials: the next 50 years. Large scale randomised evidence of moderate benefits. BMJ. 1998;317:1170.
19. Claxton K. Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. Health Econ. 1999;8:269-74.
20. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeill BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making. 1985;5:157-77.
21. Critchfield GC, Willard KE. Probabilistic analysis of decision trees using Monte Carlo simulation. Med Decis Making. 1986;6:85-92.
22. Thompson KM, Burmaster DE, Crouch EAC. Monte Carlo techniques for quantitative uncertainty analysis in public health risk assessments. Risk Anal. 1992;12:53-63.
23. Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in decision analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996. p 247-75.
24. Commonwealth Department of Health, Housing and Community Services. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra, Australia: APGS; 1992.
25. Ontario Ministry of Health. Ontario Guidelines for Economic Analyses of Pharmaceutical Products. Ontario (Canada): Ministry of Health; 1994.
26. Langley PC, Donaldson C, eds. Formulary submission guidelines for the Blue Cross and Blue Shield of Colorado and Nevada. Structure, application and manufacturer responsibilities. Pharmacoeconomics. 1999;16:211-24.
27. Claxton K, Sculpher NJS, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence. Lancet. 2002;360:711-5.
28. National Institute for Clinical Excellence. Guidance for manufacturers and sponsors. 2001. Available from: URL: www.nice.org.uk
29. DerSimonian R, Laird N. Meta-analysis of clinical trials. Control Clin Trials. 1986;7:177-88.
30. Thompson SG. Why sources of heterogeneity in meta-analyses should be investigated. BMJ. 1994;309:1351-5.
31. Lau J, Ioannidis JPA, Schmid CH. Summing up evidence: one answer is not always enough. Lancet. 1998;351:123-7.
32. Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ. 1999;8:257-61.
33. Heitian DF. Fieller's method and net health benefits. Health Econ. 2000;9:327-35.
34. Laska EM, Meisner M, Siegel C, Wanderling J. Statistical cost-effectiveness analysis of two treatments based on net health benefits. Stat Med. 2001;20:1279-302.
35. O'Hagan A, Stevens JW. A framework for cost-effectiveness analysis from clinical trial data. Health Econ. 2001;10:303-15.
36. Claxton K, Thompson KM. A dynamic programming approach to efficient clinical trial design. J Health Econ. 2001;20:797-822.
37. Bernardo JM, Smith AFM. Bayesian Theory. New York: Wiley; 1994.
38. O'Hagan A. Kendall's Advanced Theory of Statistics. Volume 2B, Bayesian Inference. London: Edward Arnold; 1994.
39. Hazen GB. Factored stochastic trees: a tool for solving complex temporal medical decision models. Med Decis Making. 1993;13:227-36.
40. Hazen GB, Pellissier JM. Recursive utility for stochastic trees. Oper Res. 1996;44:788-809.
41. Hazen GB, Pellissier JM, Sounderpandian J. Stochastic-tree models in medical decision making. Interfaces. 1998;28:64-80.
42. Hazen G. Preference factoring for stochastic trees. Manage Sci. 2000;46:389-403.
43. Beck JR, Pauker S. The Markov process in medical prognosis. Med Decis Making. 1983;3:419-58.
44. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Health Econ. 1983;13:322-38.
45. Grimmett GDR, Stirzaker DR. Probability and Random Processes. 2nd ed. Oxford (UK): Oxford University Press; 1992.
46. Shadish WR, Haddock CK. Combining stimates of effect size. In: Cooper H, Hedges LV, eds. The Handbook of Research Synthesis. New York: Russell Sage Foundation; 1994. p 261-81.
47. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Systematic reviews of trials and other studies. Health Technol Assess. 1998;2:1-276.
48. Gelman A, Carlin JG, Stern HS, Rubin DB. Bayesian Data Analysis. London: Chapman and Hall; 1995.
49. Deeks JJ. Issues on the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med. 2002;21:1575-600.
50. Rubin DB. A new perspective. In: Wachter KW, Straf ML, eds. The Future of Meta-analysis. New York: Russell Sage Foundation; 1990.
51. Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random effects regression model for meta-analysis. Stat Med. 1995;14:395-411.
52. Thompson SG, Smith TC, Sharp SJ. Investigating underlying risk as a source of heterogeneity in meta-analysis. Stat Med. 1997;16:2741-758.
53. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 1999;18:2693-708.
54. O'Hagan A, Kennedy MC, Oakley JE. Uncertainty analysis and other inference tools for complex computer codes. In: Bernardo JM, Berger JO, Dawid AP, Smith AFM, eds. Bayesian Statistics 6. Oxford (UK): Clarendon; 1998. p 503-24.
55. Rasmussen CE, Ghahramani Z. Bayesian Monte Carlo. 2002. Available from: URL: http://www-2.cs.cmu.edu/Groups/NIPS/NIPS2002/NIPS2002preproceedings/ papers/revised/AA01-draft.pdf
56. Oakley J, O'Hagan A. Probabilistic Sensitivity Analysis of Complex Models: A Bayesian Approach. Report no. 525/02. Department of Probability and Statistics, University of Sheffield; 2002.
57. Stevenson MD, Oakley J, Chilcott JB. Gaussian process modelling in conjunction with individual patient simulation modelling. A case study describing the calculation of cost-effectiveness ratios for the treatment of osteoporosis. DEEMS Workshop Synthesizing the Evidence for Economic Evaluation; 2002 Apr 11-12; Oxford, UK.
58. Eddy DM, Hasselblad V, Shachter R. Meta-analysis by the Confidence Profile Method. London: Academic Press; 1992.
59. Dilks DW, Canale RP, Meier PG. Development of Bayesian Monte Carlo techniques for water quality model uncertainty. Ecol Model. 1992;62:149-62.
60. Brand KP, Small MJ. Updating uncertainty in an integrated risk assessment: conceptual framework and methods. Risk Anal. 1995;15:719-31.
61. Sohn MD, Small MJ, Pantazidou M. Reducing uncertainty in site characterisation using Bayes Monte Carlo methods. Journal of Environmental Engineering. 2000;126:893-902.
62. Ades AE, Cliffe S. Markov Chain Monte Carlo estimation of a multi-parameter decision model: consistency of evidence and the accurate assessment of uncertainty. Med Decis Making. 2002; 22:359-71.
63. Carlin JG, Louis TA. Bayes and Empirical Bayes Methods for Data Analysis. 2nd ed. Boca Raton (FL): Chapman & Hall/CRC; 2000.
64. Smith TC, Spiegelhalter DJ, Thomas SL. Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med. 1995;14:2685-99.
65. Warn DE, Thompson SG, Spiegelhalter DJ. Bayesian random effects meta-analysis of trials with binary outcomes: method for absolute risk difference and relative risk scales. Stat Med. 2002;21:1601-23.
66. Abrams K, Sanso B. Approximate Bayesian inference for random effects meta-analysis. Stat Med. 1998;17:201-18.
67. Claxton K, Ades AE. Efficient research design: an application of value of information analysis to an economic model of zanamivir. Proceedings of the 24th Meeting of the Society for Medical Decision Making; 2002 Oct 20-23; Baltimore, MD.
68. Johnson NL, Kotz S, Kemp AW. Distributions in Statistics: Discrete Distributions. New York: Wiley; 1992.